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Disrupting integrin transmembrane domain
heterodimerization increases ligand binding affinity,
not valency or clustering
Bing-Hao Luo*, Christopher V. Carman*, Junichi Takagi†, and Timothy A. Springer*‡
*The CBR Institute for Biomedical Research and Department of Pathology, Harvard Medical School, 200 Longwood Avenue, Boston, MA 02115; and
†Institute for Protein Research, Laboratory of Protein Synthesis and Expression, Osaka University, 3-2 Yamadaoka, Suita, Osaka 565-0871, Japan
Contributed by Timothy A. Springer, December 20, 2004
Residues important in the interaction between the 23-residue
transmembrane (TM) domains of the integrin IIb- and 3-subunits
were identified by mutating each non-Leu residue to Leu. Leu
substitutions of IIb at G972, G976, and T981, and of 3 at I693 and
G708, increased ligand binding. Substitutions with other amino
acids at IIbG972 and 3G708 could also increase ligand binding.
The results are consistent with and extend the helical interface
between the integrin - and -subunit TM domains previously
defined by cysteine scanning and disulfide bond formation. We
differentiated between affinity- and valency-based modes of ac-
tivation by TM domain mutations. The mutant IIb W967C forms
disulfide-linked IIb-subunits within an (IIb3)2 tetramer. This
tetramer behaved as an ideal model for the valency mode of
regulation, because it exhibited significantly increased binding to
multivalent but not monovalent ligands and basally retained the
bent conformation. By contrast, the activating Leu mutants
showed increased binding to the monovalent, ligand-mimetic
PAC-1 Fab and increased exposure of ligand-induced binding site
(LIBS) epitopes, suggesting that they partially adopt an extended
conformation. Furthermore, the previously described 3G708N
mutation in Chinese hamster ovary cells enhanced ligand binding
affinity, not valency, and did not alter cell-surface clustering as
defined by confocal microscopy. Our studies provide evidence that
disrupting the integrin heterodimeric TM helix–helix interface
activates ligand binding mainly by increasing the monomeric
affinity for ligand, but not the receptor valency, i.e., clustering.
Integrins are noncovalently associated heterodimeric cell-adhesion molecules that transmit signals bidirectionally across the
plasma membrane and regulate many biological functions including
wound healing, cell differentiation, and cell migration. Integrins
bind to ligands in the extracellular matrix and on cell surfaces. The
‘‘avidity,’’ or overall strength, of cellular adhesive interactions
results from both the affinity of individual receptor–ligand bonds
and the valency, or the total number of bonds formed. The affinity
of integrins for ligands is conformationally regulated (1–4). On
physiological cell surfaces, integrins can assume multiple confor-
mations, each with a distinct affinity. Various studies have indicated
that close apposition of the membrane-proximal regions of each
subunit and the overall bent structure of the extracellular domain
are hallmarks for the low-affinity state of integrins, whereas the
extended conformation, with separated legs, represents the high-
affinity state (5–9). On the other hand, the valency of integrins for
ligands is regulated by changes in their cell-surface distribution.
Although a variety of studies suggest that integrin clustering serves
to enhance the propensity to form initial adhesions with multivalent
substrates (10–14), others have shown that valency regulation does
not precede ligand binding, but instead functions in adhesion
strengthening after binding to multivalent ligands (15–23).
Although considerable progress has been made, the role of
integrin transmembrane (TM) domains in integrin signaling still
remains controversial. We previously used disulfide crosslinking
studies to determine the helical interface between integrin -
and -subunit TM domains and showed that restraining this
specific heterodimeric helical interface with disulfide bonds
maintains integrins in the low-affinity state (8). By contrast, Li
et al. (11, 24, 25) have shown that in detergent micelles, integrin
TM domains have the potential to form homooligomers rather
than heterodimers. Based on two mutations, with most experi-
ments on the mutation 3G708N, they hypothesized that the
homomeric associations between TM segments provide a driving
force for integrin cell-surface oligomerization (i.e., clustering),
thereby enhancing binding to multivalent ligands (11). However,
homomeric interactions were only demonstrated with model TM
peptides in detergent micelles, and not with intact integrins on
cells. The basis for enhanced ligand binding by the 3G708N
mutation characterized in this study thus remained unclear.
Here, we use full-length integrin IIb3 expressed on the surface
of mammalian cells to study the effects of mutations of the TM
domains. Previously we used cysteine scanning to introduce disul-
fides that maintained association of IIb and 3 TM domains and
showed that this prevented activation. Here we use the converse
approach of Leu scanning to perturb TM domain association and
screen for activating mutations. We show that substitution with Leu
of residues located at the heterodimeric interface defined in the
previous study activates ligand binding, suggesting that the activat-
ing effect of the TM mutations is a consequence of the disruption
of the helical interface between the IIb and 3 TM domains. We
demonstrate that activation is a consequence of conformational
changes in the extracellular domain and increased affinity for
monomeric ligand. Contrasting results are obtained by crosslinking
of IIb TM domains to form (IIb3)2 tetramers. Tetramers show no
extracellular domain conformational change and increased multi-
meric, but not monomeric, affinity for ligand.
Materials and Methods
Plasmid Construction and Transient Transfection. Plasmids coding
for full-length human IIb and 3 were subcloned into pEFV5-
HisA or pcDNA3.1Myc-His() as described in ref. 5. Mutants
were made by using site-directed mutagenesis with the
QuikChange kit (Stratagene), and DNA sequences were con-
firmed before being transfected into 293T cells by using calcium
phosphate precipitation (26).
Soluble Fibrinogen, PAC-1 IgM, and PAC-1 Fab Binding Assay. Ligand-
mimetic IgM PAC-1 was from Becton Dickinson, PAC-1 Fab was
a generous gift from S. Shattil (27), and the activating anti-IIb
mAb PT25-2 was a generous gift from M. Handa (28). Tran-
siently transfected 293T cells or stably transfected Chinese
hamster ovary (CHO) cells in 20 mM Hepes with 150 mM NaCl
(HBS) supplemented with 5.5 mM glucose and 1% BSA were
Abbreviations: TM, transmembrane; FITC, fluorescein isothiocyanate; CHO, Chinese ham-
ster ovary; MFI, mean fluorescence intensity; LIBS, ligand-induced binding site.
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incubated with f luorescein-labeled fibrinogen (30 gml),
PAC-1 IgM (10 gml), or PAC-1 Fab (10 gml) in the
presence of 1 mM EDTA, 5 mM Ca2, or 1 mM Mn2 plus 10
gml PT25-2 at room temperature for 30 min. For fibrinogen
binding, cells were coincubated with Cy3 dye-conjugated anti-3
mAb AP3 (Cy3-AP3) to a final concentration of 10 gml. For
PAC-1 binding, cells were washed with HBS once and suspended
with HBS with 1 mM Ca2, 10 gml FITC-conjugated anti-
mouse IgM, and 10 gml Cy3-AP3. For PAC-1 Fab binding,
cells were washed once and suspended with HBS with 1 mM
Ca2 and 10 gml FITC-conjugated anti-mouse IgG. Cells were
incubated at 0°C for 30 min and then subjected to flow cytom-
etry. Binding is presented as specific mean fluorescence intensity
(MFI) of FITC-conjugated anti-mouse IgM or fibrinogen ex-
pressed as a percentage of the MFI of Cy3-AP3.
LIBS Expression. The anti-LIBS mAb AP5 was from the Fifth
International Leukocyte Workshop (29), LIBS1, LIBS6 (30), and
PMI-1 (31) were from M. H. Ginsberg, and D3 was from L. K.
Jennings (32). LIBS expression was measured as described in ref.
33. In brief, cells in HBS supplemented with 5.5 mM glucose and
1% BSA were incubated in the presence of 5 mM Ca2 or 1 mM
Mn2 plus 100 M GRGDSP peptide ligand for 30 min at room
temperature and then with LIBS mAbs AP5, LIBS1, LIBS6, D3,
and PMI-1 (10 gml) at 0°C for 30 min, followed by staining with
FITC-conjugated anti-mouse IgG and flow cytometry. LIBS bind-
ing is presented as MFI of FITC-conjugated anti-mouse IgG as a
percentage of the MFI of Cy3-AP3.
Integrin Clustering and Confocal Microscopy. CHO cells stably
expressing wild-type IIb3 and mutant IIb3 (11) were kindly
provided by J. Bennett (University of Pennsylvania, Philadel-
phia). Cells in culture medium were incubated with Cy3-AP3 (10
gml) at 37°C for 30 min in the absence or presence of rabbit
polyclonal anti-mouse IgG (10 gml) and cytochalasin-D (400
nM), followed by fixation with 3.7% formaldehyde. Confocal
imagining was performed with a Bio-Rad Radiance 2000 laser-
scanning confocal system coupled to an Olympus BX50WI
microscope and a 100 water immersion objective. All image
processing was performed with OPENLAB software (Improvision,
Lexington, MA). For each condition, the integrin cell-surface
distribution patterns of at least 200 cells, from randomly selected
fields, were scored as being either ‘‘even’’ (i.e., exhibiting
predominantly even cell-surface distribution) or ‘‘macroclus-
tered’’ (i.e., exhibiting significant levels of uneven or patchy
cell-surface distribution).
Results
Leu Scanning Shows That Mutations of Several Residues at the
Helix–Helix Interface Activate Ligand Binding. Studies on glyco-
phorin A TM domains have suggested that Leu substitutions on
average disrupt formation of TM homodimers more than sub-
stitutions with other hydrophobic residues studied, i.e., Ala, Cys,
Val, Ile, and Met (34). We therefore serially mutated all non-Leu
residues in the 23 residue integrin IIb and 3 TM domains to Leu
(Fig. 1A). Mutant IIb-subunits were coexpressed with wild-type
3-subunits, mutant 3-subunits were coexpressed with wild-
type IIb-subunits, and both were screened for enhanced binding
to the soluble, multivalent, ligand-mimetic PAC-1 IgM (Fig. 1 B
and C). Under activating conditions (in the presence of Mn2
and PT25-2), all mutants bound PAC-1 IgM at levels similar to
wild type. In the absence of activation, i.e., in Ca2, wild-type
IIb3 and most mutants exhibited essentially no PAC-1 binding.
By contrast, three mutants, IIbG972L, IIbG976L, and
3G708L, bound PAC-1 IgM at nearly maximal levels, and two
others, IIbT981L and 3I693L, bound partially. We extended
Fig. 1. Leu scanning of the IIb3 TM domains. (A) Sequences of the IIb3 TM regions. The predicted TM segments are boxed. (B and C) Soluble PAC-1 IgM binding
of 293T transfectants expressing integrins with Leu substitutions in the IIb (A) or 3 (B) TM domains in the presence of 5 mM Ca2 (open bars) or 1 mM Mn2
plus 10 gml mAb PT25-2 (filled bars). Binding was measured with two-color immunofluorescence (see Materials and Methods) and is expressed as the MFI of
PAC-1 staining as a percentage of MFI of staining with AP3 mAb. Data are representative of two independent experiments. (D) Relative orientation between
the IIb and 3 TM domain -helices as determined by disulfide scanning of residues shown between dashed lines (8). Activating residues are shown as black circles,
partially activating residues are shown as gray circles, and others are shown as white circles.




































our previously generated structural model from crosslinking
studies (8) to the C termini of the TM domains assuming ideal
-helices and found that all of these activating residues, with the
exception of IIbT981L, map to the IIb–3 interface (Fig. 1D).
The inconsistency regarding IIbT981L may suggest deviation
from ideal helices associated with an interacting coiled-coil
structure; however, it is noteworthy that mutant IIbT981L was
only partly activating and, in contrast to all other mutants, was
expressed poorly on the cell surface relative to wild type (data
not shown).
Dependence of Activation on the Specific Amino Acid Substitution.
We selected two residues that were activated when mutated to
Leu, IIbG972 and 3G708, for additional mutagenesis studies.
These two residues were mutated to Ala, Cys, or Asn. At residue
IIb972, the substitutions G972A and G972C were not activating,
showing that in contrast to Leu, smaller hydrophobic side chains
were not activating (Fig. 2 A and B). However, the more bulky,
polar G972N substitution was activating, although somewhat less
than the G972L substitution. At residue 3708, the G708A and
G708N substitutions were not activating, whereas the G708C
mutation was activating, although less so than G708L (Fig. 2).
Disulfide-Bonded IIb3 Tetramer Is an Ideal Model for Studying
Valency Effect. We previously showed that cysteine mutant
IIbW967C spontaneously and efficiently formed a ho-
modimeric disulfide bond when cotransfected with the 3-
subunit, thereby forming a covalently linked cell-surface in-
tegrin tetramer (IIbW967C3)2 (8) (Fig. 3A). In 293T
transfectants, the tetramer could be recognized by all tested
mAbs to constitutive IIb3 epitopes, including AP3, 7E3,
10E5, HA5, and AP2 (data not shown), indicating a native fold
for this disulfide-linked integrin.
Soluble fibrinogen (Fig. 3B) and PAC-1 IgM (Fig. 3C) bound
IIbW967C3 more efficiently than wild-type IIb3 basally in
Ca2, as well as after activation with Mn2, PT25-2Ca2, or
PT25-2Mn2. Notably, in Ca2 the efficiency of IIbW967C3
tetramer binding to PAC-1 IgM, with potentially 10 binding sites
per molecule, was enhanced more than binding to fibrinogen, a
divalent ligand. This result suggests that the tetrameric mutant
is highly sensitive to the valency of the ligand. Indeed, when
binding to the monovalent ligand PAC-1 Fab was assayed under
basal conditions in Ca2, no binding to IIbW967C3 tetramer
was found (Fig. 4).
LIBS mAbs were used to determine the overall conformation
of the IIbW967C3 mutant. All of the LIBS mAbs bound
poorly to the tetrameric mutant in Ca2, similarly to wild type
(Fig. 3D), suggesting that the mutant receptor is basally in the
bent, resting conformation. This finding, together with the lack
of effect on monomeric affinity for PAC-1 Fab, demonstrates
that the observed increased binding to PAC-1 IgM and fibrin-
ogen under basal conditions by IIbW967C3 (Fig. 3 B and C)
must be attributed to an effect on valency. Thus, this mutant
represents an ideal model of valency-regulated ligand binding.
Monovalent Ligand-Mimetic PAC-1 Fab Binding Shows That the Acti-
vating Effect of Leu Mutations of the Integrin TM Domains Is Due to
Increased Affinity. As described above, the IIbW967C mutant did
not bind to monomeric PAC-1 Fab in Ca2 (Fig. 4). By contrast,
Fig. 2. Effects of different amino acid substitutions on IIb3 activation.
Fibrinogen (A) and PAC-1 IgM (B) binding to 293T transfectants was deter-
mined in the presence of 5 mM Ca2 (open bars) or 1 mM Mn2 plus 10 gml
mAb PT25-2 (filled bars). Binding was determined by immunofluorescence as
described in Fig. 1.
Fig. 3. Disulfide-linked IIb3 tetramer provides a model for valency regu-
lation. (A) Schematic drawing of disulfide-linked IIb3 tetramer. The - and
-subunits are continuous lines and dashed lines, respectively. The membrane
is shown as a gray line. The location of the IIb C967 disulfide bond is shown.
(B and C) Soluble fibrinogen and PAC-1 IgM binding to 293T cell transfectants
in the presence of Ca2 (white bars), Mn2 (gray bars), PT25-2 (hatched bars),
or MnPT25-2 (black bars). Binding was determined by immunofluorescence
as described in Fig. 1. (D) LIBS exposure. Binding of five different anti-LIBS
mAbs is expressed as the MFI of mAb staining as a percentage of MFI of
staining with AP3 mAb.











































the activating Leu mutations, IIbG972L, IIbG976L, and
3G708L, all bound PAC-1 Fab efficiently (Fig. 4). These
mutants were activated similarly to the 3N305T mutant (Fig. 4),
which introduces an N-glycosylation site into the interface
between the 3 I-like and hybrid domains and stabilizes the open,
high-affinity conformation of the integrin headpiece (9, 33, 35).
High-affinity monomeric binding was also induced by mutation
to GAAKR of the GFFKR motif at the junction between the IIb
TM and cytoplasmic domains (Fig. 4). Mutation of this motif has
long been known to activate ligand binding (36) and has been
shown to induce integrin TM domain separation (8) and cyto-
plasmic domain separation (7). Overall, the data suggest that the
activating effect of the IIbG972L, IIbG976L, and 3G708L
mutants is due to increased affinity rather than valency. As a
further control, the IIbG975L and 3G708N mutants, which did
not increase multimeric affinity, also did not detectably increase
monomeric affinity in 293T transfectants (Fig. 4).
TM Domain Mutations That Increase Monomeric Affinity Partially
Increase LIBS Epitope Expression. The mutant receptors were
characterized for binding to two representative LIBS mAbs.
Under basal conditions, the activating Leu mutants, IIbG972L,
IIbG976L, and 3G708L, as well as the GAAKR mutant, but
not the nonactivating IIbG975L mutant, bound LIBS6 mAb to
essentially maximal levels, i.e., comparably to binding in the
presence of Mn2 and RGD (Fig. 5A). The same activating Leu
mutants and the GAAKR mutant, but not IIbG975L, also
elevated binding to mAb D3 under basal conditions, as shown by
comparison with wild type. However, in contrast to the LIBS6
epitope, expression of the D3 epitope on all mutants could still
be significantly increased by Mn2 and RGD (Fig. 5B). The same
results were obtained in EDTA as in Ca2, excluding a contri-
bution by ligands in the culture medium to LIBS epitope
expression. By contrast to the effect of activating TM domain
mutations on D3 epitope exposure, the wedge mutant 3N305T
bound D3 and other anti-IIb3 LIBS antibodies at maximal
levels in Ca2, i.e., comparably to binding in the presence of
Mn2 and RGD (data not shown) (33). Similarly, the 1 wedge
mutant bound anti-1 LIBS antibodies maximally (35). These
results suggest that, unlike the glycan-wedge mutations that
strongly stabilize the integrin in the open, extended conforma-
tion (33, 35), the activating Leu and GAAKR mutations increase
affinity for ligand by shifting the equilibrium toward the ex-
tended conformation of the receptor.
In CHO Transfectants, 3G708N Exhibits Increased Ligand Binding
Activity as a Consequence of Increased Affinity Rather Than Increased
Valency. Above, we showed that the 3G708N mutation has no
detectable effect on ligand binding by IIb3 in 293T cell
transfectants. Li et al. (11) have shown that 3G708N mutation
in CHO transfectants leads to increased ligand binding com-
pared to wild type. We confirmed that in CHO IIb3 trans-
fectants, 3G708N increased binding to the multivalent ligand-
mimetic PAC-1 IgM, although to a level 20% of that of the
wedge mutant 3N305T (Fig. 6A). The 3G708N mutant also
showed increased binding to PAC-1 Fab (Fig. 6B). Binding to
multimeric PAC-1 IgM and monomeric PAC-1 Fab by the
3G708N mutant was comparably increased (Fig. 6 A and B).
In contrast, the tetrameric IIbW967C mutant shows binding to
multimeric PAC-1 IgM, but not to PAC-1 Fab (Fig. 4).
Therefore, it is concluded that the partially activating effect of
3G708N in CHO cells is due to an effect on affinity rather
than valency.
To determine whether the 3G708N mutation induced mac-
roclustering, i.e., areas of the cell surface with increased integrin
density that are 200 nm in diameter and therefore detectable
by microscopy, we conducted confocal microscopy studies of
CHO-cell IIb3 transfectants. Under basal conditions in Ca2,
the vast majority of the cells expressing wild-type and 3G708N
IIb3 demonstrated relatively evenly distributed cell-surface
integrin (Fig. 6C). Only 4% and 5% of cells, respectively, showed
any substantial macroclustering. We also ranked the cells by
expression of IIb3 and quantitated clustering in the 10%
highest expressing cells in each group. These cells, which ex-
pressed about three to five more IIb3 than the mean, also
showed comparable macroclustering for wild type (9%) and
3G708N (12%). The presence of similar but small subpopula-
tions of cells with macroclustering illustrates the importance of
population analysis in addition to showing micrographs of
individual cells. After treatment with cytochalasin-D to increase
integrin cell-surface diffusivity (37), integrins remained unclus-
Fig. 4. PAC-1 Fab binding activity of 293T cell transfectants. The MFI of PAC-1
Fab staining is expressed as a percentage of MFI of staining with AP3 mAb.
Fig. 5. Exposure of LIBS epitopes by activating TM domain mutations. The
MFI of anti-LIBS mAbs LIBS6 (A) and D3 (B) is expressed as a percentage of MFI
of staining with AP3 mAb.




































tered on the vast majority of cells (Fig. 6C). Only a slight increase
in the number of cells with macroclustering was seen, and the
percentages were similar for wild type (13%) and 3G708N (16%).
On the other hand, crosslinking cell-surface IIb3 with primary and
secondary antibodies promoted significant IIb3 macroclustering
(76% for wild type, and 73% for 3G708N) in a manner that was
further enhanced by concomitant cytochalasin-D treatment (96%
macroclustering for wild type, and 94% for 3G708N) (Fig. 6C).
Importantly, under all conditions, no substantial difference was
observed in the propensity of wild-type and 3G708N IIb3 to
form cell-surface macroclusters.
Discussion
This investigation has yielded insights into the role that TM
domains play in integrin activation. Previously we used cys-
teine scanning mutagenesis to identify the -helical interface
between the N-terminal regions of the integrin - and -sub-
unit TM domains and showed that disulfide bonds introduced
into this interface maintained the integrin in the low-affinity
state (8). Here, we use the converse approach of Leu scanning
mutagenesis to perturb TM domain association. The activating
mutations map to the same interface as previously defined
with activation-restraining disulfides. This finding strongly
suggests that activation is a consequence of disruption of the
helical TM interface between the integrin - and -subunits.
Moreover, we extended previous results by subjecting the
entire TM segments to mutagenesis. With the exception of one
anomalous mutation that was not well expressed and only
partially activating, the results suggest that the previously
defined -helical interface extends all of the way across the
membrane. We further showed that a variety of the activating
mutations both increase monovalent ligand binding and induce
conformational changes in the extracellular domain, consistent
with our previous finding that association between the TM
domains maintains the low-affinity integrin conformation.
We previously identified a mutant, IIbW967C, that when
cotransfected with wild-type 3 efficiently forms disulfide-
linked integrin tetramers on the cell surface (8). We showed
here that these tetramers are basally in the bent conformation
and exhibit increased binding to multivalent, but not mono-
valent, ligands. These results are canonical for the valency (or
‘‘clustering’’) mode of regulation. Thus, IIbW967C represents
an ideal model for the valency mode of activation. By contrast,
Leu and several other amino acid substitutions introduced into
the TM helical interface, mutation of the GFFKR motif
(IIbGAAKR), and introduction of a glycan wedge into the
I-like hybrid domain interface (3N305T) increase monomeric
affinity for ligand. Thus, the IIbW967C mutation increases
valency, whereas all other activating mutations in the TM
domains characterized here, including IIb3G708N, act by
increasing affinity, but not valency, for ligand.
Our results fail to support a major role for the TM domains
in regulating cell-surface oligomerization of integrins, as has
recently been suggested by others (11, 25). The mutant
3G708N has been described to stabilize homotrimerization of
isolated TM domains in detergent micelles and suggested to
enhance ligand binding in CHO cells by driving cell-surface
integrin clustering (11). We have confirmed that this mutation
partially increased binding for multimeric ligand in CHO
cells; however, 3G708N binding to monomeric ligand was
enhanced to the same extent. These results suggest that
3G708N activates by the affinity mode of regulation. More-
over, this mutant failed to alter the extent of cell-surface
macroclustering compared with wild-type IIb3 under a va-
riety of conditions.
The two most activating mutations we found in the IIb-
subunit, G972L and G976L, are present within a GXXXG
motif. GXXXG motifs appear to be generally important in
association between TM helices (34), and we have previously
demonstrated that this motif in IIb is in the interface with 3
in the membrane (8). Homomeric association of truncated IIb
TM domains has been demonstrated in Escherichia coli inner
membranes by reporter assays and in detergent micelles by
SDSPAGE and analytical ultracentrifugation (25). The
G972L and G976L mutations decrease homomerization in
these assays. We find that the same mutations activate binding
of soluble monovalent ligand and expression of LIBS epitopes.
The results are consistent with a similar interface involving the
IIb GXXXG motif being involved in heterodimerization with
3 and homomerization with IIb. Furthermore, the findings
that (i) G972L and G976L mutations are activating (here) and
(ii) decrease IIb homomerization (25) are compatible with
activation by separation of IIb and 3 TM domains but are
incompatible with activation by IIb homomerization.
Our results support an important role for separation of the
integrin  and  TM domains in regulating the conformation
and affinity for ligand of the extracellular domain. Notably, the
only example in which we have been able to capture homo-
meric integrin TM domain interactions with disulfide bonds is
in the resting, low-affinity conformation. The integrin dimer
that is formed binds multivalent, but not monovalent, ligands
better, demonstrating valency rather than affinity regulation.
Despite a large number of - and -subunit TM cysteine
mutations that were tested within heterodimers containing an
activating -subunit GFFKR mutation, and separation of the
- and -subunit TM domains in these mutants, none formed
disulfide-linked homomers (8). Furthermore, f luorescent res-
Fig. 6. Ligand binding and clustering of selected IIb3 mutants stably
expressed in CHO cells. (A and B) Ligand binding. PAC-1 IgM (A) and PAC-1 Fab
(B) binding of CHO cell transfectants. Binding was determined as the MFI of
PAC-1 staining as a percentage of MFI of staining with AP3 mAb. (C) Confocal
microscopy studies of integrin clustering on the cell surface. Cells expressing
wild-type IIb3 or mutant IIb3G708N were incubated with Cy3-AP3 mAb in
the absence (control) or presence of cytochalasin-D (Cyto D), anti-mouse IgG
(Abs), or anti-mouse IgGcytochalasin-D (Cyto D  Abs) at 37°C for 30 min,
followed by fixation, and subjected to confocal microscopy.











































onance energy transfer between -subunits of different inte-
grin heterodimers, or between -subunits of different integrin
heterodimers, shows that integrin activation and separation of
 and  TM domains in the plane of the membrane occurs
without giving rise to homomeric  TM domain or homomeric
 TM domain interactions (23). In the future, it will be
interesting to learn whether micro- and macroclustering of
integrins on the cell surface, which occurs only after binding
to multimeric ligands (23), brings the TM domains of integrins
sufficiently close together to drive formation of integrin - or
-subunit TM domain homomers.
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